Literature DB >> 29271563

Is metformin poised for a second career as an antimicrobial?

Faiza Malik1, Syed Faizan Mehdi1, Haroon Ali1, Priya Patel1, Anam Basharat1, Amrat Kumar1, Fnu Ashok1, Joanna Stein1,2, Wunnie Brima1, Prashant Malhotra3,2, Jesse Roth1,2.   

Abstract

Metformin, a widely used antihyperglycaemic, has a good safety profile, reasonably manageable side-effects, is inexpensive, and causes a desirable amount of weight loss. In 4 studies of patients with tuberculosis (1 prospective and 3 retrospective), metformin administration resulted in better outcomes. In mice with several models of endotoxemia, metformin diminished levels of proinflammatory cytokines and improved survival. Laboratory studies showed effectiveness of the drug on multiple pathogens, including Trichinella spiralis, Staphylococcus aureus, Pseudomonas aeruginosa, hepatitis B virus, hepatitis C virus, and human immunodeficiency virus. Metformin administration in humans and mice produced major changes in the composition of the gut microbiota. These recently discovered microbe-modulating properties of the drug have led investigators to predict wide therapeutic utility for metformin. The recent easing in United States Food and Drug Administration (FDA) guidelines regarding administration of metformin to patients with kidney disease, and reduced anxiety about patient safety in terms of lactic acidosis, increase the probability of broadening of metformin's usage as a treatment of infectious agents. In this text we review articles pertinent to metformin's effects on microorganisms, both pathogens and commensals. We highlight the possible role of metformin in a wide range of infectious diseases and a possible expansion of its therapeutic profile in this field. A systematic review was done of PubMed indexed articles that examined the effects of metformin on a wide range of pathogens. Metformin was found to have efficacy as an antimicrobial agent in patients with tuberculosis. Mice infected with Trypanosomiasis cruzi had higher survival when also treated with metformin. The drug in vitro was active against T. spiralis, S. aureus, P. aeruginosa, and hepatitis B virus. In addition there is emerging literature on its role in sepsis. We conclude that metformin may have a potential role in the therapy for multiple infectious diseases. Metformin, in addition to its traditional effects on glucose metabolism, provides anti-microbial benefits in patients with tuberculosis and in a very wide range of other infections encounters in vitro and in vivo.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Trypanosomiasis cruzi; antimicrobial; hepatitis B; metformin; sepsis; tuberculosis

Mesh:

Substances:

Year:  2018        PMID: 29271563     DOI: 10.1002/dmrr.2975

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  25 in total

Review 1.  Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence?

Authors:  Antonio Sircana; Luciana Framarin; Nicola Leone; Mara Berrutti; Francesca Castellino; Renato Parente; Franco De Michieli; Elena Paschetta; Giovanni Musso
Journal:  Curr Diab Rep       Date:  2018-09-13       Impact factor: 4.810

2.  Targeting liver stage malaria with metformin.

Authors:  Iset Medina Vera; Margarida T Grilo Ruivo; Leonardo F Lemos Rocha; Sofia Marques; Sangeeta N Bhatia; Maria M Mota; Liliana Mancio-Silva
Journal:  JCI Insight       Date:  2019-12-19

3.  Worsening Glycemia Increases the Odds of Intermittent but Not Persistent Staphylococcus aureus Nasal Carriage in Two Cohorts of Mexican American Adults.

Authors:  Heather T Essigmann; Craig L Hanis; Stacia M DeSantis; William B Perkison; David A Aguilar; Goo Jun; D Ashley Robinson; Eric L Brown
Journal:  Microbiol Spectr       Date:  2022-05-18

4.  Metformin Suppresses Development of the Echinococcus multilocularis Larval Stage by Targeting the TOR Pathway.

Authors:  Julia A Loos; Valeria A Dávila; Klaus Brehm; Andrea C Cumino
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

5.  Mechanism of higher risk for COVID-19 in diabetes: a mask to lift.

Authors:  Chen Fang; Yun Huang; Heming Guo; Yihui Sun; Hui Li; Xuna Bian; Haixia Guan; Ji Hu
Journal:  Endocrine       Date:  2020-07-23       Impact factor: 3.633

6.  A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin.

Authors:  Jamie N Justice; Sriram Gubbi; Ameya S Kulkarni; Jenna M Bartley; George A Kuchel; Nir Barzilai
Journal:  Geroscience       Date:  2020-09-09       Impact factor: 7.713

7.  Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies.

Authors:  Huoyan Liang; Xianfei Ding; Lifeng Li; Tian Wang; Quancheng Kan; Lexin Wang; Tongwen Sun
Journal:  Crit Care       Date:  2019-02-18       Impact factor: 9.097

Review 8.  Metformin and COVID-19: From cellular mechanisms to reduced mortality.

Authors:  A J Scheen
Journal:  Diabetes Metab       Date:  2020-08-01       Impact factor: 6.041

9.  Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review.

Authors:  Xinyu Yu; Ling Li; Liangtao Xia; Xin Feng; Fan Chen; Shiyi Cao; Xiang Wei
Journal:  BMC Infect Dis       Date:  2019-10-17       Impact factor: 3.090

Review 10.  Role of Metformin on Osteoblast Differentiation in Type 2 Diabetes.

Authors:  Lin Jiating; Ji Buyun; Zhang Yinchang
Journal:  Biomed Res Int       Date:  2019-11-26       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.